Pfizer Change in Assets/Liabilities 2010-2025 | PFE
Pfizer annual/quarterly change in assets/liabilities history and growth rate from 2010 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
- Pfizer change in assets/liabilities for the quarter ending June 30, 2025 was $-6.908B, a 0.54% increase year-over-year.
- Pfizer change in assets/liabilities for the twelve months ending June 30, 2025 was $-15.899B, a 27.33% decline year-over-year.
- Pfizer annual change in assets/liabilities for 2024 was $-1.08B, a 2.86% increase from 2023.
- Pfizer annual change in assets/liabilities for 2023 was $-1.05B, a 83.85% decline from 2022.
- Pfizer annual change in assets/liabilities for 2022 was $-6.5B, a 139.4% decline from 2021.
Pfizer Annual Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$-1,080 |
| 2023 |
$-1,050 |
| 2022 |
$-6,500 |
| 2021 |
$16,498 |
| 2020 |
$1,391 |
| 2019 |
$-1,366 |
| 2018 |
$315 |
| 2017 |
$-60 |
| 2016 |
$-270 |
| 2015 |
$900 |
| 2014 |
$511 |
| 2013 |
$-3,939 |
| 2012 |
$-3,172 |
| 2011 |
$1,694 |
| 2010 |
$296 |
| 2009 |
$-851 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$141.684B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
